CPA
ACAD icon

Capital Performance Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Capital Performance Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25
Closed -$385 – 186
2024
Q3 		$385 Buy
+25
New +$417 ﹤0.01% 2365

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Capital Performance Advisors's ACAD Position: Q4 2024 in Review

Capital Performance Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 25 shares — an estimated $385 sold.

Capital Performance Advisors first reported a position in ACAD in Q3 2024 and held it in 1 quarter. The position peaked at $385 in Q3 2024. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • Capital Performance Advisors reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 25 Acadia Pharmaceuticals shares in Q4 2024, an estimated $385.
  • Capital Performance Advisors first reported a position in Acadia Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Acadia Pharmaceuticals position peaked at $385 in Q3 2024.
  • 296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.